Keros receives FDA Orphan Drug designation for KER-065 in Duchenne muscular dystrophy

Keros Therapeutics, Inc.

• FDA granted Orphan Drug designation for KER-065, a TGF-ß family protein-targeting therapy for DMD.
• Designation provides potential 7-year market exclusivity, tax credits, and fee waivers if approved.
• KER-065 is advancing toward a Phase 2 clinical trial in patients with DMD, as stated by CEO.
• DMD affects fewer than 200,000 people in the U.S., qualifying for Orphan Drug status.
• Keros (KROS) is a clinical-stage biopharma focused on TGF-ß signaling disorders.